查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600590

細胞和基因治療製造服務市場：按類型、適應症、應用和最終用戶 - 2025-2030 年全球預測

Cell & Gene Therapy Manufacturing Services Market by Type (Cell Therapy, Gene Therapy), Indication (Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年細胞和基因治療製造服務市值為173.4億美元，預計2024年將達到199.8億美元，複合年成長率為15.81%，2030年將達到484.5億美元，預計將達到1000萬美元。

細胞和基因療法製造服務包括涉及製造基於細胞和基因修飾療法的廣泛流程。這些服務包括細胞培養、病毒載體製造、基因改造、品管、法規遵循等。對此類服務的需求源於個人化醫療和生物技術的快速發展，這些發展推動了針對特定遺傳疾病、癌症和其他疾病的客製化治療的需求。其應用涵蓋臨床和商業製造，服務於多個最終用途行業，包括醫療保健提供者、製藥公司和研究機構。市場成長受到研發投資增加、技術進步和慢性病盛行率上升等關鍵因素的影響。製造流程自動化數位化、改進可擴展性解決方案以及創新非病毒載體以使其更安全、更具成本效益方面存在重大機會。然而，市場成長可能面臨挑戰，例如高開發成本、複雜的監管環境以及圍繞細胞和基因療法運輸和儲存的物流問題。一個潛在的創新領域是開發封閉式系統製造技術，最大限度地減少污染風險並提高效率。擴大製造商和生物技術公司之間的夥伴關係可以加速採用並培養強大的供應鏈。了解這些動態可以提供對市場靈活而複雜的本質的寶貴見解。競爭格局要求公司始終掌握不斷發展的技術和監管指南。為了利用成長機會，相關人員應優先考慮協作努力，重點最佳化生產流程，並投資 CRISPR 和人工智慧主導分析等新技術。總體而言，該市場顯示出強大的潛力，但需要戰略遠見和敏捷性來克服獨特的挑戰。

主要市場統計
基準年[2023] 173.4億美元
預測年份 [2024] 199.8億美元
預測年份 [2030] 484.5億美元
複合年成長率（%） 15.81%

市場動態：針對快速發展的細胞和基因治療製造服務市場揭示的關鍵市場洞察

細胞和基因治療製造服務市場正在因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 癌症等針對性疾病高發生
    • CDMO加大對藥物研發與先進技術的投入
    • 由於疾病早期診斷的趨勢不斷成長，關注個人化醫療
  • 市場限制因素
    • 與細胞和基因治療製造服務相關的高營運成本
  • 市場機會
    • 細胞/基因療法開發中先進分析技術的出現
    • 改善細胞和基因治療製造的供應鏈
  • 市場挑戰
    • 細胞和基因治療製造中的品管和污染問題

波特五力：引領細胞與基因治療製造服務市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解對細胞和基因治療製造服務市場的外部影響

外部宏觀環境因素在塑造細胞和基因治療製造服務市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解細胞和基因治療製造服務市場的競爭狀況

對細胞和基因治療製造服務市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣細胞和基因治療製造服務市場供應商的績效評估

FPNV定位矩陣是評估細胞和基因治療製造服務市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類了供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症和其他目標疾病的發生率更高
      • CDMO加大對藥物研發與尖端技術的投入
      • 隨著早期診斷趨勢的增加，關注個人化醫療
    • 抑制因素
      • 與細胞和基因治療製造服務相關的高營運成本
    • 機會
      • 細胞和基因治療發展中先進分析技術的出現
      • 改善細胞和基因治療製造的供應鏈
    • 任務
      • 細胞/基因治療藥物製造的品管與污染問題
  • 市場區隔分析
    • 類型：間質幹細胞在組織修復和發炎治療的應用
    • 適應症：擴大腫瘤治療的潛力，為患有各種惡性的患者提供個人化醫療
    • 應用：早期產品的客製化細胞和基因治療製造服務的顯著優勢
    • 最終用戶：高度偏好學術和研究機構的具成本效益服務
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章細胞和基因治療製造服務市場：按類型

  • 細胞療法
    • 同種異體的
      • 同種異體造血幹細胞
      • 同種異體誘導性多功能幹細胞
      • 間質幹細胞
      • 同種異體自然殺手細胞
      • 同種異體T細胞
    • 自體移植
      • 自體造血幹細胞
      • 間質幹細胞
      • 自體自然殺手細胞
      • 自體T細胞
    • 病毒載體
      • 腺結合病毒載體
      • 逆轉錄病毒載體
  • 基因治療
    • 非病毒載體
    • 寡核苷酸

第7章依適應症分類的細胞和基因治療製造服務市場

  • 心血管疾病
  • 中樞神經系統疾病
  • 感染疾病
  • 腫瘤疾病
  • 眼科疾病
  • 整形外科疾病

第8章細胞/基因治療製造服務市場：依應用分類

  • 臨床製造
  • 商業製造

第9章細胞與基因治療製造服務市場：依最終用戶分類

  • 學術研究所
  • 製藥和生物技術公司

第10章美洲細胞與基因治療製造服務市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太細胞與基因治療製造服務市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的細胞和基因治療製造服務市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FUJIFILM投資2億美元擴大業務
    • eXmoor Pharma 開設 GMP 設施，成為細胞和基因治療領域的全方位服務 CDMO 合作夥伴
    • Thermo Fisher Scientific 在加州大學舊金山分校開設細胞治療設施，以加速突破性治療方法的開發

公司名單

  • uBriGene Biosciences Inc.
  • Bluebird Bio, Inc.
  • Cell Therapies Pty Ltd.
  • Merck KGaA
  • Catalent, Inc.
  • Miltenyi Biotec BV & Co. KG
  • Nikon Corporation
  • Takara Holdings Inc.
  • Charles River Laboratories International, Inc.
  • General Electric Company
  • Cell and Gene Therapy Catapult
  • Boehringer Ingelheim International GmbH
  • c-LEcta GmbH
  • Advanced BioScience Laboratories, Inc.
  • Thermo Fisher Scientific, Inc.
  • Novartis AG
  • Cell-Easy SAS
  • Samsung Biologics Co., Ltd
  • Recipharm AB
  • FUJIFILM Diosynth Biotechnologies
  • Resonac Corporation
  • Exmoor Pharma Concepts Limited
  • AGC Biologics
  • Bio-Techne Corporation
  • Wuxi Apptec Co., Ltd.
  • Lonza Group
  • Minaris Regenerative Medicine GmbH
  • Oxford Biomedica PLC
  • F. Hoffmann-La Roche Ltd.
Product Code: MRR-BB6269D1414B

The Cell & Gene Therapy Manufacturing Services Market was valued at USD 17.34 billion in 2023, expected to reach USD 19.98 billion in 2024, and is projected to grow at a CAGR of 15.81%, to USD 48.45 billion by 2030.

Cell and gene therapy manufacturing services encompass a wide range of processes involved in producing cell-based and gene-modified therapies. These services include cell culture, viral vector production, genetic modification, quality control, and regulatory compliance. The necessity for such services arises from the rapid advancements in personalized medicine and biotechnology that drive demand for tailored therapies targeting specific genetic diseases, cancers, and other conditions. Their application spans across clinical and commercial manufacturing, serving multiple end-use industries such as healthcare providers, pharmaceutical companies, and research institutions. The market's growth is influenced by key factors such as increasing investments in R&D, technological advancements, and rising prevalence of chronic diseases. Significant opportunities lie in automation and digitalization of manufacturing processes, improved scalability solutions and innovations in non-viral vectors, which can enhance safety and cost-effectiveness. However, market growth can face challenges such as high development costs, complex regulatory landscapes, and logistical issues surrounding the transport and storage of cell and gene therapies. A potential area for innovation is the development of closed-system manufacturing technologies to minimize contamination risk and improve efficiency. Expanding partnerships between manufacturers and biotech companies could accelerate adoption and foster a robust supply chain. Understanding these dynamics provides valuable insight into the market's flexible yet complex nature. The competitive landscape requires companies to stay abreast of evolving technologies and regulatory guidelines. To leverage growth opportunities, stakeholders should prioritize collaborative efforts, focus on optimizing production processes, and invest in new technologies like CRISPR and AI-driven analytics. Overall, while the market shows robust potential, navigating its inherent challenges requires strategic foresight and agility.

KEY MARKET STATISTICS
Base Year [2023] USD 17.34 billion
Estimated Year [2024] USD 19.98 billion
Forecast Year [2030] USD 48.45 billion
CAGR (%) 15.81%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell & Gene Therapy Manufacturing Services Market

The Cell & Gene Therapy Manufacturing Services Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High Incidence of Cancer and Other Target Diseases
    • Increasing Investments in Pharmaceutical R&D and Advanced Technologies by CDMOs
    • Focus on the Personalized Medicine with the Rising Tendency Towards Early Disease Diagnosis
  • Market Restraints
    • High Operational Costs Associated With Cell & Gene Therapy Manufacturing Services
  • Market Opportunities
    • Emergence of Advanced Analytical Technologies in Development of Cell & Gene Therapy
    • Improvement in the Supply Chain of Cell & Gene Therapy Manufacturing
  • Market Challenges
    • Quality Control and Contamination Issues in Cell & Gene Therapy Production

Porter's Five Forces: A Strategic Tool for Navigating the Cell & Gene Therapy Manufacturing Services Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell & Gene Therapy Manufacturing Services Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell & Gene Therapy Manufacturing Services Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell & Gene Therapy Manufacturing Services Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell & Gene Therapy Manufacturing Services Market

A detailed market share analysis in the Cell & Gene Therapy Manufacturing Services Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell & Gene Therapy Manufacturing Services Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell & Gene Therapy Manufacturing Services Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Manufacturing Services Market, highlighting leading vendors and their innovative profiles. These include uBriGene Biosciences Inc., Bluebird Bio, Inc., Cell Therapies Pty Ltd., Merck KGaA, Catalent, Inc., Miltenyi Biotec B.V. & Co. KG, Nikon Corporation, Takara Holdings Inc., Charles River Laboratories International, Inc., General Electric Company, Cell and Gene Therapy Catapult, Boehringer Ingelheim International GmbH, c-LEcta GmbH, Advanced BioScience Laboratories, Inc., Thermo Fisher Scientific, Inc., Novartis AG, Cell-Easy SAS, Samsung Biologics Co., Ltd, Recipharm AB, FUJIFILM Diosynth Biotechnologies, Resonac Corporation, Exmoor Pharma Concepts Limited, AGC Biologics, Bio-Techne Corporation, Wuxi Apptec Co., Ltd., Lonza Group, Minaris Regenerative Medicine GmbH, Oxford Biomedica PLC, and F. Hoffmann-La Roche Ltd..

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Manufacturing Services Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Cell Therapy and Gene Therapy. The Cell Therapy is further studied across Allogeneic, Autologous, and Viral Vector. The Allogeneic is further studied across Allogeneic Hematopoietic Stem Cells, Allogeneic Induced Pluripotent Stem Cells, Allogeneic Mesenchymal Stem Cells, Allogeneic Natural Killer Cells, and Allogeneic T-cells. The Autologous is further studied across Autologous Hematopoietic Stem Cells, Autologous Mesenchymal Stem Cells, Autologous Natural Killer Cells, and Autologous T-cells. The Viral Vector is further studied across Adeno-associated Virus Vectors and Retroviral Vectors. The Gene Therapy is further studied across Non-viral Vector and Oligonucleotides.
  • Based on Indication, market is studied across Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases, Oncology Diseases, Ophthalmology Diseases, and Orthopedic Diseases.
  • Based on Application, market is studied across Clinical Manufacturing and Commercial Manufacturing.
  • Based on End-User, market is studied across Academic & Research Institutes and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High Incidence of Cancer and Other Target Diseases
      • 5.1.1.2. Increasing Investments in Pharmaceutical R&D and Advanced Technologies by CDMOs
      • 5.1.1.3. Focus on the Personalized Medicine with the Rising Tendency Towards Early Disease Diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. High Operational Costs Associated With Cell & Gene Therapy Manufacturing Services
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of Advanced Analytical Technologies in Development of Cell & Gene Therapy
      • 5.1.3.2. Improvement in the Supply Chain of Cell & Gene Therapy Manufacturing
    • 5.1.4. Challenges
      • 5.1.4.1. Quality Control and Contamination Issues in Cell & Gene Therapy Production
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Applications of autologous mesenchymal stem cells for tissue repair and anti-inflammatory treatments
    • 5.2.2. Indication: Growing potential of oncology therapies for personalized medicine in patients with various malignancies
    • 5.2.3. Application: Significant benefits of customized cell & gene therapy manufacturing services for early-stage products
    • 5.2.4. End-User: Higher preferences for cost-effective services from academic and research institutes
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell & Gene Therapy Manufacturing Services Market, by Type

  • 6.1. Introduction
  • 6.2. Cell Therapy
    • 6.2.1. Allogeneic
      • 6.2.1.1. Allogeneic Hematopoietic Stem Cells
      • 6.2.1.2. Allogeneic Induced Pluripotent Stem Cells
      • 6.2.1.3. Allogeneic Mesenchymal Stem Cells
      • 6.2.1.4. Allogeneic Natural Killer Cells
      • 6.2.1.5. Allogeneic T-cells
    • 6.2.2. Autologous
      • 6.2.2.1. Autologous Hematopoietic Stem Cells
      • 6.2.2.2. Autologous Mesenchymal Stem Cells
      • 6.2.2.3. Autologous Natural Killer Cells
      • 6.2.2.4. Autologous T-cells
    • 6.2.3. Viral Vector
      • 6.2.3.1. Adeno-associated Virus Vectors
      • 6.2.3.2. Retroviral Vectors
  • 6.3. Gene Therapy
    • 6.3.1. Non-viral Vector
    • 6.3.2. Oligonucleotides

7. Cell & Gene Therapy Manufacturing Services Market, by Indication

  • 7.1. Introduction
  • 7.2. Cardiovascular Diseases
  • 7.3. Central Nervous System Disorders
  • 7.4. Infectious Diseases
  • 7.5. Oncology Diseases
  • 7.6. Ophthalmology Diseases
  • 7.7. Orthopedic Diseases

8. Cell & Gene Therapy Manufacturing Services Market, by Application

  • 8.1. Introduction
  • 8.2. Clinical Manufacturing
  • 8.3. Commercial Manufacturing

9. Cell & Gene Therapy Manufacturing Services Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Pharmaceutical & Biotechnology Companies

10. Americas Cell & Gene Therapy Manufacturing Services Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cell & Gene Therapy Manufacturing Services Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cell & Gene Therapy Manufacturing Services Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Fujifilm to Invest USD 200 Million to Expand
    • 13.3.2. eXmoor Pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities
    • 13.3.3. Thermo Fisher Scientific Opens Cell Therapy Facility at UCSF to Accelerate Development of Breakthrough Therapies

Companies Mentioned

  • 1. uBriGene Biosciences Inc.
  • 2. Bluebird Bio, Inc.
  • 3. Cell Therapies Pty Ltd.
  • 4. Merck KGaA
  • 5. Catalent, Inc.
  • 6. Miltenyi Biotec B.V. & Co. KG
  • 7. Nikon Corporation
  • 8. Takara Holdings Inc.
  • 9. Charles River Laboratories International, Inc.
  • 10. General Electric Company
  • 11. Cell and Gene Therapy Catapult
  • 12. Boehringer Ingelheim International GmbH
  • 13. c-LEcta GmbH
  • 14. Advanced BioScience Laboratories, Inc.
  • 15. Thermo Fisher Scientific, Inc.
  • 16. Novartis AG
  • 17. Cell-Easy SAS
  • 18. Samsung Biologics Co., Ltd
  • 19. Recipharm AB
  • 20. FUJIFILM Diosynth Biotechnologies
  • 21. Resonac Corporation
  • 22. Exmoor Pharma Concepts Limited
  • 23. AGC Biologics
  • 24. Bio-Techne Corporation
  • 25. Wuxi Apptec Co., Ltd.
  • 26. Lonza Group
  • 27. Minaris Regenerative Medicine GmbH
  • 28. Oxford Biomedica PLC
  • 29. F. Hoffmann-La Roche Ltd.

LIST OF FIGURES

  • FIGURE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH PROCESS
  • FIGURE 2. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC NATURAL KILLER CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC T-CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS NATURAL KILLER CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS T-CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY OLIGONUCLEOTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY OPHTHALMOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ORTHOPEDIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 244. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 253. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 262. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 271. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 272. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 280. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY CE